Jing Xiang1, Ellen Maue2, Han Tong3, Francesco T Mangano4, Hansel Greiner5, Jeffrey Tenney2. 1. MEG Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. Electronic address: Jing.xiang@cchmc.org. 2. MEG Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. 3. MEG Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States; Neuroscience Graduate Program, University of Cincinnati, Cincinnati, OH, United States. 4. Division of Neurosurgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States. 5. Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Abstract
OBJECTIVE: One barrier hindering high frequency brain signals (HFBS, >80 Hz) from wide clinical applications is that the brain generates both pathological and physiological HFBS. This study was to find specific biomarkers for localizing epileptogenic zones (EZs). METHODS: Twenty three children with drug-resistant epilepsy and age/sex matched healthy controls were studied with magnetoencephalography (MEG). High frequency oscillations (HFOs, > 4 oscillatory waveforms) and high frequency spikes (HFSs, > 1 spiky or sharp waveforms) in 80-250 Hz and 250-600 Hz bands were blindly detected with an artificial intelligence method and validated with visual inspection. The magnitude of HFOs and HFSs were quantified with spectral analyses. Sources of HFSs and HFOs were localized and compared with clinical EZs determined by invasive recordings and surgical outcomes. RESULTS: HFOs in 80-250 Hz and 250-600 Hz were identified in both epilepsy patients (18/23, 12/23, respectively) and healthy controls (6/23, 4/23, respectively). HFSs in 80-250 Hz and 250-600 Hz were detected in patients (16/23, 11/23, respectively) but not in healthy controls. A combination of HFOs and HFSs localized EZs for 22 (22/23, 96%) patients. CONCLUSIONS: The results indicate, for the first time, that HFSs are a newer and more specific biomarker than HFOs for localizing EZs because HFOs appeared in both epilepsy patients and healthy controls while HFSs appeared only in epilepsy patients.
OBJECTIVE: One barrier hindering high frequency brain signals (HFBS, >80 Hz) from wide clinical applications is that the brain generates both pathological and physiological HFBS. This study was to find specific biomarkers for localizing epileptogenic zones (EZs). METHODS: Twenty three children with drug-resistant epilepsy and age/sex matched healthy controls were studied with magnetoencephalography (MEG). High frequency oscillations (HFOs, > 4 oscillatory waveforms) and high frequency spikes (HFSs, > 1 spiky or sharp waveforms) in 80-250 Hz and 250-600 Hz bands were blindly detected with an artificial intelligence method and validated with visual inspection. The magnitude of HFOs and HFSs were quantified with spectral analyses. Sources of HFSs and HFOs were localized and compared with clinical EZs determined by invasive recordings and surgical outcomes. RESULTS: HFOs in 80-250 Hz and 250-600 Hz were identified in both epilepsy patients (18/23, 12/23, respectively) and healthy controls (6/23, 4/23, respectively). HFSs in 80-250 Hz and 250-600 Hz were detected in patients (16/23, 11/23, respectively) but not in healthy controls. A combination of HFOs and HFSs localized EZs for 22 (22/23, 96%) patients. CONCLUSIONS: The results indicate, for the first time, that HFSs are a newer and more specific biomarker than HFOs for localizing EZs because HFOs appeared in both epilepsy patients and healthy controls while HFSs appeared only in epilepsy patients.
Authors: Maeike Zijlmans; Premysl Jiruska; Rina Zelmann; Frans S S Leijten; John G R Jefferys; Jean Gotman Journal: Ann Neurol Date: 2012-02 Impact factor: 10.422
Authors: Jing Xiang; Abraham Korman; Kasun M Samarasinghe; Xiaopei Wang; Fawen Zhang; Hui Qiao; Bo Sun; Fengbin Wang; Howard H Fan; Elizabeth A Thompson Journal: J Neurosci Methods Date: 2014-10-18 Impact factor: 2.390
Authors: Eleonora Tamilia; Eun-Hyoung Park; Stefania Percivati; Jeffrey Bolton; Fabrizio Taffoni; Jurriaan M Peters; P Ellen Grant; Phillip L Pearl; Joseph R Madsen; Christos Papadelis Journal: Ann Neurol Date: 2018-09-04 Impact factor: 10.422
Authors: Maryse A van 't Klooster; Nicole E C van Klink; Willemiek J E M Zweiphenning; Frans S S Leijten; Rina Zelmann; Cyrille H Ferrier; Peter C van Rijen; Willem M Otte; Kees P J Braun; Geertjan J M Huiskamp; Maeike Zijlmans Journal: Ann Neurol Date: 2017-05 Impact factor: 10.422